{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:01:18Z","timestamp":1780617678534,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100032738","name":"Brainlab","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-48935-z","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:26:05Z","timestamp":1776165965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility and utility of a tablet-based digital neurocognitive assessment following radiosurgery for brain metastases"],"prefix":"10.1038","volume":"16","author":[{"given":"Eyub Y.","family":"Akdemir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"DiStefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thailin Companioni","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazmin","family":"Odia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Press","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Jay","family":"Wieczorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsook C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjini","family":"Tolakanahalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonso N.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minesh P.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"48935_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1200\/jco.2004.05.128","volume":"22","author":"CA Meyers","year":"2004","unstructured":"Meyers, C. A. et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial. J. Clin. Oncol. 22, 157\u2013165. https:\/\/doi.org\/10.1200\/jco.2004.05.128 (2004).","journal-title":"J. Clin. Oncol."},{"key":"48935_CR2","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/cco.0000000000000581","volume":"31","author":"MB Coomans","year":"2019","unstructured":"Coomans, M. B., van der Linden, S. D., Gehring, K. & Taphoorn, M. J. B. Treatment of cognitive deficits in brain tumour patients: Current status and future directions. Curr. Opin. Oncol. 31, 540\u2013547. https:\/\/doi.org\/10.1097\/cco.0000000000000581 (2019).","journal-title":"Curr. Opin. Oncol."},{"key":"48935_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.893264","volume":"12","author":"EJ Lehrer","year":"2022","unstructured":"Lehrer, E. J. et al. The cognitive effects of radiotherapy for brain metastases. Front. Oncol. 12, 893264. https:\/\/doi.org\/10.3389\/fonc.2022.893264 (2022).","journal-title":"Front. Oncol."},{"key":"48935_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05682-1","volume":"12","author":"AL Whittaker","year":"2022","unstructured":"Whittaker, A. L., George, R. P. & O\u2019Malley, L. Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: A systematic review and meta-analysis. Sci. Rep. 12, 2135. https:\/\/doi.org\/10.1038\/s41598-022-05682-1 (2022).","journal-title":"Sci. Rep."},{"key":"48935_CR5","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1016\/s1470-2045(13)70308-5","volume":"14","author":"NU Lin","year":"2013","unstructured":"Lin, N. U. et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: Neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 14, e407-416. https:\/\/doi.org\/10.1016\/s1470-2045(13)70308-5 (2013).","journal-title":"Lancet Oncol."},{"key":"48935_CR6","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.21037\/apm-21-1545","volume":"11","author":"D Hartgerink","year":"2022","unstructured":"Hartgerink, D. et al. Quality of life among patients with 4 to 10 brain metastases after treatment with whole-brain radiotherapy vs. stereotactic radiotherapy: A phase III, randomized, Dutch multicenter trial. Ann. Palliat. Med. 11, 1197\u20131209. https:\/\/doi.org\/10.21037\/apm-21-1545 (2022).","journal-title":"Ann. Palliat. Med."},{"key":"48935_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11675-8","volume":"23","author":"B Adegboyega","year":"2023","unstructured":"Adegboyega, B. et al. Patient reported outcomes following whole brain radiotherapy in patients with brain metastases in NSIA-LUTH Cancer Center. BMC Cancer 23, 1233. https:\/\/doi.org\/10.1186\/s12885-023-11675-8 (2023).","journal-title":"BMC Cancer"},{"key":"48935_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijrobp.2023.04.030","volume":"117","author":"V Gondi","year":"2023","unstructured":"Gondi, V. et al. Sustained preservation of cognition and prevention of patient-reported symptoms with hippocampal avoidance during whole-brain radiation therapy for brain metastases: Final results of NRG Oncology CC001. Int. J. Radiat. Oncol. Biol. Phys. 117, 571\u2013580. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.04.030 (2023).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"48935_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/s1470-2045(10)70294-1","volume":"12","author":"JS Wefel","year":"2011","unstructured":"Wefel, J. S., Vardy, J., Ahles, T. & Schagen, S. B. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 12, 703\u2013708. https:\/\/doi.org\/10.1016\/s1470-2045(10)70294-1 (2011).","journal-title":"Lancet Oncol."},{"key":"48935_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.jpainsymman.2015.06.019","volume":"50","author":"F Joly","year":"2015","unstructured":"Joly, F. et al. Impact of cancer and its treatments on cognitive function: Advances in research from the Paris International Cognition and Cancer Task Force Symposium and update since 2012. J. Pain Symptom Manage. 50, 830\u2013841. https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.06.019 (2015).","journal-title":"J. Pain Symptom Manage."},{"key":"48935_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/neuonc\/nov186","volume":"18","author":"EJ Habets","year":"2016","unstructured":"Habets, E. J. et al. Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: A prospective study. Neuro Oncol. 18, 435\u2013444. https:\/\/doi.org\/10.1093\/neuonc\/nov186 (2016).","journal-title":"Neuro Oncol."},{"key":"48935_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.clon.2021.01.003","volume":"33","author":"WCM Schimmel","year":"2021","unstructured":"Schimmel, W. C. M. et al. Group and individual change in cognitive functioning in patients with 1 to 10 brain metastases following Gamma Knife Radiosurgery. Clin Oncol (R Coll Radiol) 33, 314\u2013321. https:\/\/doi.org\/10.1016\/j.clon.2021.01.003 (2021).","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"48935_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1586\/era.12.34","volume":"12","author":"C Caine","year":"2012","unstructured":"Caine, C., Mehta, M. P., Laack, N. N. & Gondi, V. Cognitive function testing in adult brain tumor trials: Lessons from a comprehensive review. Expert Rev. Anticancer Ther. 12, 655\u2013667. https:\/\/doi.org\/10.1586\/era.12.34 (2012).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"48935_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s13760-021-01744-9","volume":"122","author":"K Leemans","year":"2022","unstructured":"Leemans, K. & De Ridder, M. Cognition: Development of a cognitive testing battery on the iPad for the evaluation of patients with brain Mets. Acta Neurol. Belg. 122, 145\u2013152. https:\/\/doi.org\/10.1007\/s13760-021-01744-9 (2022).","journal-title":"Acta Neurol. Belg."},{"key":"48935_CR15","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.3171\/2022.3.Focus21726","volume":"52","author":"VM Butenschoen","year":"2022","unstructured":"Butenschoen, V. M., Ahlfeld, J., Meyer, B. & Krieg, S. M. Digital cognitive testing using a tablet-based app in patients with brain tumors: a single-center feasibility study comparing the app to the gold standard. Neurosurg. Focus. 52, E7. https:\/\/doi.org\/10.3171\/2022.3.Focus21726 (2022).","journal-title":"Neurosurg. Focus"},{"key":"48935_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11060-025-05038-5","volume":"174","author":"EY Akdemir","year":"2025","unstructured":"Akdemir, E. Y. et al. Integrating a novel tablet-based digital neurocognitive assessment tool in brain metastases patients. J. Neurooncol. 174, 121\u2013129. https:\/\/doi.org\/10.1007\/s11060-025-05038-5 (2025).","journal-title":"J. Neurooncol."},{"key":"48935_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/arclin\/acq084","volume":"26","author":"AD Hinton-Bayre","year":"2011","unstructured":"Hinton-Bayre, A. D. Calculating the test-retest reliability co-efficient from normative retest data for determining reliable change. Arch. Clin. Neuropsychol. 26, 76\u201377. https:\/\/doi.org\/10.1093\/arclin\/acq084 (2011).","journal-title":"Arch. Clin. Neuropsychol."},{"key":"48935_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/arclin\/acr120","volume":"27","author":"K Duff","year":"2012","unstructured":"Duff, K. Evidence-based indicators of neuropsychological change in the individual patient: Relevant concepts and methods. Arch. Clin. Neuropsychol. 27, 248\u2013261. https:\/\/doi.org\/10.1093\/arclin\/acr120 (2012).","journal-title":"Arch. Clin. Neuropsychol."},{"key":"48935_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1037\/0894-4105.10.1.120","volume":"10","author":"L Ingraham","year":"1996","unstructured":"Ingraham, L. & Aiken, C. B. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology 10, 120\u2013124 (1996).","journal-title":"Neuropsychology"},{"key":"48935_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11910-012-0264-9","volume":"12","author":"JS Wefel","year":"2012","unstructured":"Wefel, J. S. & Schagen, S. B. Chemotherapy-related cognitive dysfunction. Curr. Neurol. Neurosci. Rep. 12, 267\u2013275. https:\/\/doi.org\/10.1007\/s11910-012-0264-9 (2012).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"48935_CR21","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/s1470-2045(09)70263-3","volume":"10","author":"EL Chang","year":"2009","unstructured":"Chang, E. L. et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol. 10, 1037\u20131044. https:\/\/doi.org\/10.1016\/s1470-2045(09)70263-3 (2009).","journal-title":"Lancet Oncol."},{"key":"48935_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown, P. D. et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial. JAMA 316, 401\u2013409. https:\/\/doi.org\/10.1001\/jama.2016.9839 (2016).","journal-title":"JAMA"},{"key":"48935_CR23","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/s1470-2045(17)30441-2","volume":"18","author":"PD Brown","year":"2017","unstructured":"Brown, P. D. et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): A multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 18, 1049\u20131060. https:\/\/doi.org\/10.1016\/s1470-2045(17)30441-2 (2017).","journal-title":"Lancet Oncol."},{"key":"48935_CR24","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1001\/jamaoncol.2022.5049","volume":"8","author":"JD Palmer","year":"2022","unstructured":"Palmer, J. D. et al. Association of long-term outcomes with stereotactic radiosurgery vs whole-brain radiotherapy for resected brain metastasis: A secondary analysis of the N107C\/CEC.3 (Alliance for Clinical Trials in Oncology\/Canadian Cancer Trials Group) randomized clinical trial. JAMA Oncol. 8, 1809\u20131815. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5049 (2022).","journal-title":"JAMA Oncol."},{"issue":"2","key":"48935_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1227\/01.Neu.0000249272.64439.B1","volume":"60","author":"EL Chang","year":"2007","unstructured":"Chang, E. L. et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 60(2), 277\u2013283. https:\/\/doi.org\/10.1227\/01.Neu.0000249272.64439.B1 (2007).","journal-title":"Neurosurgery"},{"key":"48935_CR26","unstructured":"Organization, W. H. WHO guideline recommendations on digital interventions for health system strengthening. (2019)."},{"key":"48935_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.123.032733","volume":"13","author":"I De Anda-Duran","year":"2024","unstructured":"De Anda-Duran, I. et al. Comparing cognitive tests and smartphone-based assessment in 2 US community-based cohorts. J. Am. Heart Assoc. 13, e032733. https:\/\/doi.org\/10.1161\/jaha.123.032733 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"48935_CR28","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/neuonc\/noaa192","volume":"22","author":"MT Milano","year":"2020","unstructured":"Milano, M. T. et al. Executive summary from American Radium Society\u2019s appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases. Neuro Oncol. 22, 1728\u20131741. https:\/\/doi.org\/10.1093\/neuonc\/noaa192 (2020).","journal-title":"Neuro Oncol."},{"key":"48935_CR29","unstructured":"Center, P. R. Latinos in the U.S. | Data on U.S. Hispanics. (2023)."},{"key":"48935_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/arclin\/16.2.183","volume":"16","author":"GL Iverson","year":"2001","unstructured":"Iverson, G. L. Interpreting change on the WAIS-III\/WMS-III in clinical samples. Arch. Clin. Neuropsychol. 16, 183\u2013191 (2001).","journal-title":"Arch. Clin. Neuropsychol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48935-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48935-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48935-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:03:28Z","timestamp":1780614208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48935-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["48935"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-48935-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EYA, JD, TCR: None, YO: Consulting fees from Istari Oncology, PharPoint Research; Participation on a Data Safety Monitoring Board or Advisory Board in Actuate, GammaTile, Novocure; other financial or non-financial interests in Blue Earth Diagnostics, BMS, Cantex Pharmaceuticals, Chimerix, CNS Pharmaceuticals, Exelixis, Karyopharm, MimiVax LLC, VBI Vaccines. RHP, DJW, YCL, RT: None, ANG: Honoraria from ViewRay, Inc., Elekta AB, IBA; Ownership interest of Atlantic Health Solutions (uPlan), LLC., MWM: Stock shareholder in Light Helmets, Deinde Medical; honoraria from Insightec; consulting fees from Stryker, Diende, Light Helmets, Insight tech, Zap surgical., MDH: Grant support from Florida Department of Health, Grant 22L01. Proton Therapy Cooperative Group of North America (PTCOG-NA) Treasurer (unpaid); Proton Therapy Cooperative Group (PTCOG) Pediatric Subcommittee Co-Chair (unpaid); Proton Collaborative Group (PCG) Executive Council Representative for Miami Cancer Institute (unpaid). , MPM: Consulting Fees from Telix, Zap, Xoft, Kazia Therapeutics, Novocure; Mevion Technological Advisory Board; NRG Brain Tumor Committee Chair; Leadership (unpaid) Board of Directors, Xcision; Stock in Chimerix., RK: Honoraria from Elekta AB, Accuray Inc., Novocure Inc., ViewRay Inc., Elsevier Inc., Brainlab, Peerview Institute for Medical Education, GT Medical Technologies, and Ion Beam Applications; consulting fees from Kazia Therapeutics, Elekta AB, ViewRay Inc., Castle Biosciences, Novocure Inc.; institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, AstraZeneca, Exelixis, ViewRay Inc., Brainlab, Cantex Pharmaceuticals, Kazia Therapeutics and Ion Beam Applications; support for travel or meeting attendance by Elekta AB, Accuray Inc., Novocure Inc., Peerview Institute for Medical Education, Brainlab, ViewRay Inc.; and participation on an advisory board for Viewray Medical Advisory Board, GT Medical Technologies Data Safety Monitoring Board, Insightec Ltd, Plus Therapeutics, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Miami Cancer Institute, Baptist Health South Florida (protocol code 2020-KOT-004; March 9, 2021). All participants provided written informed consent prior to enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}],"article-number":"17421"}}